USDA Agricultural Research Services and ChemImage Corporation Join Forces to Combat Food Safety Issues

ChemImage is pleased to announce publication of the results of a collaborative study with the FDA to characterize the thermodynamics of a highly unstable polymorph of acetaminophen.  The Journal of Pharmaceutical and Biomedical Analysis, a peer reviewed journal, published Raman detected differential scanning calorimetry of polymorphic transformations in acetaminophen (doi: 10.1016/j.jpba.2008.09.008).

This publication outlines the application of a method for polymorph characterization which combines differential scanning calorimetry (DSC) and Raman microscopy. Interest in the polymorphic forms of acetaminophen comes as a result of the poor compression properties of the form used commercially in common pain relievers.  An understanding of thermally driven polymorphic transformations is essential to the development and, ultimately, the use of another form that has improved compression properties with the same pharmacological effects.

“This is an important achievement as it opens the door to study other polymorphic transitions within the pharmaceutical arena,” stated David Tuschel, co-author and Principal Materials Scientist at ChemImage.  

Through the simultaneous use of these individual methods, scientists from both organizations have worked to unambiguously identify polymorphic transitions, including the presence of a third form which is highly unstable and to date has not been isolated for powder X-ray diffraction.

This work comes as a product of the Cooperative Research and Development Agreement (CRADA) which ChemImage and the FDA signed in 2006, and was entered into for the design of protocols for validating Raman Chemical Imaging for applications in pharmaceutical research and process control.  

About ChemImage Corporation

ChemImage Corporation is a Pittsburgh based company committed to making the world healthier and safer through dramatic advancements in chemical imaging technology. The company combines proprietary, state-of-the-art imaging sensors, algorithms and analytical software to solve the world's most challenging health and safety issues.

ChemImage seeks to provide an Awareness of Things™ (AoT™) to a global audience, using the company's innovation platforms to provide people with unprecedented levels of vision, information and situational knowledge about their surroundings in their everyday lives. To accomplish this goal, the firm develops technologies for chemical and biological applications across many global industries; including life sciences, bio-medical, security, threat detection, anatomic pathology, forensics and diagnostics. 

For more information, contact ChemImage.